CPVT1-iPS cell-derived cardiomyocytes exhibited arrhythmias, delayed afterdepolarizations after catecholaminergic stimulation, and higher amplitudes and longer durations of spontaneous Ca2+ release.
Patient-specific iPSC-derived cardiomyocytes carrying a novel RYR2 mutation successfully recapitulate the CPVT1 arrhythmic phenotype in vitro, offering a platform for disease modeling and drug testing.
BACKGROUND/AIMS: Induced pluripotent stem (iPS) cells generated from accessible adult cells of patients with genetic diseases open unprecedented opportunities for exploring the pathophysiology of human diseases in vitro. Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is an inherited cardiac disorder that is caused by mutations in the cardiac ryanodine receptor type 2 gene (RYR2) and is characterized by stress-induced ventricular arrhythmia that can lead to sudden cardiac death in young individuals. The aim of this study was to generate iPS cells from a patient with CPVT1 and determine whether iPS cell-derived cardiomyocytes carrying patient specific RYR2 mutation recapitulate the disease phenotype in vitro. METHODS: iPS cells were derived from dermal fibroblasts of healthy donors and a patient with CPVT1 carrying the novel heterozygous autosomal dominant mutation p.F2483I in the RYR2. Functional properties of iPS cell derived-cardiomyocytes were analyzed by using whole-cell current and voltage clamp and calcium imaging techniques. RESULTS: Patch-clamp recordings revealed arrhythmias and delayed afterdepolarizations (DADs) after catecholaminergic stimulation of CPVT1-iPS cell-derived cardiomyocytes. Calcium imaging studies showed that, compared to healthy cardiomyocytes, CPVT1-cardiomyocytes exhibit higher amplitudes and longer durations of spontaneous Ca(2+) release events at basal state. In addition, in CPVT1-cardiomyocytes the Ca(2+)-induced Ca(2+)-release events continued after repolarization and were abolished by increasing the cytosolic cAMP levels with forskolin. CONCLUSION: This study demonstrates the suitability of iPS cells in modeling RYR2-related cardiac disorders in vitro and opens new opportunities for investigating the disease mechanism in vitro, developing new drugs, predicting their toxicity, and optimizing current treatment strategies.
Fatima et al. (Sat,) conducted a other in Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1). CPVT1-iPS cell-derived cardiomyocytes (RYR2 p.F2483I mutation) vs. Healthy donor iPS cell-derived cardiomyocytes was evaluated on Arrhythmias, delayed afterdepolarizations (DADs), and calcium release events. CPVT1-iPS cell-derived cardiomyocytes exhibited arrhythmias, delayed afterdepolarizations after catecholaminergic stimulation, and higher amplitudes and longer durations of spontaneous Ca2+ release.